Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 2:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Hormonal panel Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Menstrual Cycle TMS Plasticity Pilot

NCT07180654
View directory record Official record
Conditions
Cortical Activation
Interventions
transcranial magnetic stimulation
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
20 Years to 40 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 24, 2026, 2:50 AM EDT
Terminated Not applicable Interventional

How Gas-Filled Intragastric Balloons or Endoscopic Sleeve Gastroplasty Affect Hunger, Hunger Hormones, and Gastric Emptying Compared to Meal Replacements

NCT04306445
View directory record Official record
Conditions
Obesity
Interventions
GF-IGB: Obalon Balloon, Medically Supervised Meal Replacement Program: My New Weigh, Endoscopic sleeve gastroplasty: (ESG)
Device · Dietary Supplement · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
22 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 24, 2026, 2:50 AM EDT
Recruiting Not applicable Interventional

A Study to Prevent and Improve Sexual Health Concerns for People With Breast Cancer

NCT05910294
View directory record Official record
Conditions
Improve Sexual Health, Improve Vulvovaginal Health
Interventions
questionnaires, moisturizers
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 24, 2026, 2:50 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Hormonal Mechanisms of Sleep Restriction

NCT02256865
View directory record Official record
Conditions
Insulin Resistance
Interventions
Ketoconazole, Hydrocortisone, Testosterone, Placebo for ketoconazole, Placebo for hydrocortisone, Placebo for testosterone
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
22 Years to 45 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2023
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 24, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

Lapatinib and Trastuzumab With or Without Endocrine Therapy

NCT00548184
View directory record Official record
Conditions
Breast Cancer
Interventions
Lapatinib, Trastuzumab, Endocrine
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Sep 24, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer

NCT00274469
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
fulvestrant, anastrozole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
45 Years to 100 Years · Female only
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
5
States / cities
Frederick, Maryland • St Louis, Missouri • Teaneck, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 24, 2026, 2:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hormonal Contraceptive Health Education for Adolescent Males

NCT03400410
View directory record Official record
Conditions
Contraception Behavior
Interventions
Education Arm
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
15 Years to 21 Years · Male only
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 24, 2026, 2:50 AM EDT
Terminated Phase 2 Interventional Results available

Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer

NCT00932152
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Postmenopausal Women
Interventions
fulvestrant (Faslodex), anastrozole (Arimidex), Bevacizumab (Avastin), Best supportive care
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Sep 24, 2026, 2:50 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

CREST: Samphire Guided Care Program on Wellbeing, Work Productivity, and Quality of Life

NCT07679074
View directory record Official record
Conditions
Premenstrual Syndrome, Premenstrual Dysphoric Disorder, Dysmenorrhea, Endometriosis, Perimenopause, Menopause, Pelvic Pain
Interventions
Lutea Transcranial Direct Current Stimulation (tDCS) Device, Samphire Guided Care Program
Device · Behavioral
Lead sponsor
Samphire Group, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 24, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03049735
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
76
States / cities
Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Sep 24, 2026, 2:50 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Migraine in Adolescents

NCT05654012
View directory record Official record
Conditions
Migraine
Interventions
MRI, Thermal Stimuli, Pressure stimuli, Pain ratings, Pressure pain thresholds (PPT), Conditioned pain modulation (CPM) efficiency, Hormonal assessment, Migraine-related measures, Neural assessments, Pubertal status
Device · Behavioral · Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
10 Years to 13 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 24, 2026, 2:50 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

ITT-5 Mechanisms of Spermatogenesis in Man

NCT02147964
View directory record Official record
Conditions
Gonadotropin Deficiency
Interventions
Testosterone 1% Gel, Acyline, Dutasteride, Ketoconazole, HCG, placebo dutasteride, placebo ketoconazole
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Sep 24, 2026, 2:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention

NCT00723398
View directory record Official record
Conditions
Breast Cancer
Interventions
Lovaza 4gm oral, Raloxifene 60 Mg Oral Tablet, Raloxifene 30 Mg Oral Tablet, Lovaza 4gm & Raloxifene 30mg
Dietary Supplement · Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
35 Years to 70 Years · Female only
Enrollment
266 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Sep 24, 2026, 2:50 AM EDT
Terminated Phase 3 Interventional Results available

External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer

NCT00388804
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy, Bicalutamide, Leuprolide, Goserelin, Flutamide, Questionnaire
Procedure · Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Sep 24, 2026, 2:50 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity

NCT00439972
View directory record Official record
Conditions
Contraception
Interventions
Ortho-Cyclen (R), Ortho Evra (R), extended use of Ortho Evra (R)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 13, 2011 · Synced Sep 24, 2026, 2:50 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)

NCT04930055
View directory record Official record
Conditions
Cancer
Interventions
COVID-19 Vaccination
Biological
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
2,206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Sep 24, 2026, 2:50 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Hormonal, Metabolic, and Signaling Interactions in PAH

NCT01884051
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Scleroderma Associated Pulmonary Arterial Hypertension, Appetite Suppressant Associate PAH
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 90 Years
Enrollment
1,899 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2032
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 24, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03103087
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate, Relugolix placebo, Estradiol/norethindrone acetate placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
89
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 24, 2026, 2:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Immune Cell Changes in the Genital Tract 2 Months After Initiation of an IUD for Contraception

NCT01240811
View directory record Official record
Conditions
Genital Tract Mucosal Immunity, Genital Tract Microflora
Interventions
IUD placement, Levonorgestrel IUD, Copper T380A IUD
Drug
Lead sponsor
Sharon Achilles
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 25, 2017 · Synced Sep 24, 2026, 2:50 AM EDT
Completed Early Phase 1 Interventional

Mediators of Abnormal Reproductive Function in Obesity (MARO)

NCT01817400
View directory record Official record
Conditions
Infertility, Female, Obesity
Interventions
Microdialysis, Vascepa - Fish Oil, Aspirin, Pioglitazone
Other · Dietary Supplement · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 24, 2026, 2:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Brain Activation and Satiety in Children: Functional Magnetic Resonance Imaging

NCT02484976
View directory record Official record
Conditions
Childhood Obesity
Interventions
Family Based Behavioral Treatment
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
9 Years to 11 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Sep 24, 2026, 2:50 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Mechanisms of Post-Bariatric Hypoglycemia

NCT04428866
View directory record Official record
Conditions
Hypoglycemia
Interventions
Continuous Glucose Monitoring, activity monitor, Mixed meal tolerance test, Glucagon Sensitivity Testing, Hypoglycemic Hyperinsulinemic Clamp, analysis of fecal microbiome
Diagnostic Test
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 24, 2026, 2:50 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Comparison of Hormonal Therapy: Mediating Hot Flashes Tapering Regimens for Mediating Hot Flashes

NCT00547001
View directory record Official record
Conditions
Hot Flashes, Night Sweats
Interventions
Estradiol
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
35 Years to 70 Years · Female only
Enrollment
235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 17, 2008 · Synced Sep 24, 2026, 2:50 AM EDT
Completed Phase 1 Interventional

Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance

NCT01197170
View directory record Official record
Conditions
Solid Tumors, Advanced Cancer
Interventions
Anastrozole, Bevacizumab, Everolimus, Sorafenib, Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 24, 2026, 2:50 AM EDT